| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
| 02.03.02 |
Drugs for arrhythmias |
|
|
| 02.03.02 |
Supraventricular arrhythmias |
|
|
| 02.03.02 |
Supraventricular and ventricular arrhythmias |
|
|
Amiodarone
(tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
 Specialist intiation supported by a RICaD
Amiodarone RICaD-Sandwell only
Atrial fibrillation : Rhythm control should be used when:
symptomatic; under 65's; first time -lone AF; secondary to treated or corrected precipitant with congestive heart failure. Beta-blockers are first line, amiodarone should be used second line where structural heart disease is present
Check thyroid function and liver function every 6 months
Phototoxicity reactions possible - advise use of wide spectrum sunscreen.
Suspect pneumonitis if new or preogressive shortness of breath or cough develops
Following the policy - Items which should not routinely be prescribed in Primary Care. Patients who are established on Amiodarone should continue their prescriptions as normal
The guidance applies to new patients only
Wolverhampton
Walsall
Dudley
|
Flecainide
(tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
 Initiation under specialist supervision
Contraindicated in heart failure or abnormal left ventricular function
Rhythm control should be used when:
symptomatic; under 65's; first time -lone AF; secondary to treated or corrected precipitant with congestive heart failure. Beta-blockers are first line, flecainide is a second line option when there is no structural heart disease:
Wolverhampton
Walsall
Dudley
|
| 02.03.02 |
Ventricular arrhythmias |
|
|
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
